開拓藥業有限公司*
KINTOR PHARMACEUTICAL LIMITED
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 9939)

VOLUNTARY ANNOUNCEMENT

PHASE II CLINICAL TRIAL OF KX-826 FOR TREATMENT OF FEMALE AGA IN CHINA MET PRIMARY ENDPOINT

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the "**Company**", together with its subsidiaries, the "**Group**") to update its shareholders and potential investors on the latest business advancement of the Group.

The board (the "**Board**") of directors (the "**Directors**") is pleased to announce that the primary endpoint of phase II clinical trial (the "**Phase II Clinical Trial**") of pyrilutamide ("**KX-826**"), a potential first-in-class topical drug developed by the Group, in China for the treatment of adult female androgenetic alopecia ("**AGA**") patients was met. KX-826 has demonstrated clinically meaningful and statistically significant improvement in hair growth as measured by target area non-vellus hair count ("**TAHC**"). In addition, its safety profile was favorable.

The Phase II Clinical Trial is a multi-center, randomized, double-blind and placebo-controlled clinical study designed to evaluate the efficacy and safety of KX-826 for the treatment of AGA in female adults. Professor Jianzhong Zhang (張建中), chairman of the Department of Dermatology, Peking University People's Hospital (北京大學人民醫院), is the leading principal investigator ("**Leading PI**"). The primary endpoint for the trial is the change from baseline versus placebo in TAHC at the end of week 24.

A total of 160 female AGA patients who have met Savin Scale D3-D6 were enrolled in the Phase II Clinical Trial. Among them, 119 patients were randomly assigned to four treatment groups, including KX-826 2.5mg (0.25%) once daily ("**QD**"), KX-826 2.5mg (0.25%) twice daily ("**BID**"), KX-826 5mg (0.5%) QD and KX-826 5mg (0.5%) BID; and 41 patients were randomly assigned to placebo groups (QD and BID). The results have shown that,

(1) The TAHC of the KX-826 5mg (0.5%) QD group has increased by 11.39 hair counts per cm^2 compared with the placebo group from baseline after the treatment of 24 weeks, which was statistically significant (P=0.0087). In addition, KX-826 has demonstrated efficacy as early as at the end of week 12.

(2) The recommended dose for phase III clinical trial for female AGA in China is determined as KX-826 5mg (0.5%) QD.

(3) The overall safety profile of KX-826 was favorable. The majority of treatment emerged adverse events ("**TEAE**") were mild and similar to those of placebo. No TEAE resulting in patient withdrawal from the trial, nor death was reported.

KX-826 is an androgen receptor ("**AR**") antagonist and a potential first-in-class topical drug for the treatment of AGA and acne vulgaris. On 8 September 2021, the Company announced that the primary endpoint of the phase II clinical trial of KX-826 on male adults was met, with results demonstrating a positive efficacy and safety profile. The Company is continuing to conduct a phase III clinical trial of KX-826 in China for male AGA and has completed the enrollment of patients in its phase II clinical trial of KX-826 in the US for male AGA. For the acne vulgaris indication, the enrollment of patients in its phase II clinical trial of KX-826 in China was completed. Please refer to the announcement dated 8 September 2021, 3 August 2022 and 16 October 2022, respectively, for details.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that KX-826 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong
Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, 1 December 2022

As at the date of this announcement, the executive Directors are Dr. Youzhi Tong and Ms. Yan Lu; the non-executive Directors are Mr. Weipeng Gao, Ms. Geqi Wei and Mr. Chengwei Liu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*